[HTML][HTML] A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic …
D Sohal, S Krishnamurthi, R Tohme, X Gu… - American journal of …, 2020 - ncbi.nlm.nih.gov
Abstract DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
[HTML][HTML] A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor
O Gayet, C Loncle, P Duconseil, M Gilabert… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity
in the response to treatments. To improve the responsiveness to treatments there are two …
in the response to treatments. To improve the responsiveness to treatments there are two …
Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression
J Gao, L Wang, J Xu, J Zheng, X Man, H Wu… - Journal of Experimental …, 2013 - Springer
Background Altered gene methylation, regulated by DNA methyltransferases (DNMT) 1, 3a
and 3b, contributes to tumorigenesis. However, the role of DNMT in pancreatic ductal …
and 3b, contributes to tumorigenesis. However, the role of DNMT in pancreatic ductal …
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications
KK Wong - Cellular Oncology, 2020 - Springer
Background Pancreatic cancer or pancreatic ductal adenocarcinoma (PDAC) is one of the
most devastating cancer types with a 5-year survival rate of only 9%. PDAC is one of the …
most devastating cancer types with a 5-year survival rate of only 9%. PDAC is one of the …
Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors
DNA methyltransferase I (DNMT1) is the major methyltransferase responsible for
methylating DNA and is overexpressed in many cancers. DNMT1 is also a therapeutic target …
methylating DNA and is overexpressed in many cancers. DNMT1 is also a therapeutic target …
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine
JV Thottassery, V Sambandam, PW Allan… - Cancer chemotherapy …, 2014 - Springer
Purpose Currently approved DNA hypomethylating nucleosides elicit their effects in part by
depleting DNA methyltransferase I (DNMT1). However, their low response rates and …
depleting DNA methyltransferase I (DNMT1). However, their low response rates and …
Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase
M Hosokawa, R Seiki, S Iwakawa… - … and Biophysical Research …, 2021 - Elsevier
Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor is a novel anti-cancer drug
regulating epigenetic mechanisms. Similar to conventional anti-cancer drugs, drug …
regulating epigenetic mechanisms. Similar to conventional anti-cancer drugs, drug …
5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development
WB Parker, JV Thottassery - Journal of Pharmacology and Experimental …, 2021 - ASPET
DNA methyltransferase (DNMT) 1 is an enzyme that functions as a maintenance
methyltransferase during DNA replication, and depletion of this enzyme from cells is …
methyltransferase during DNA replication, and depletion of this enzyme from cells is …
DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
ABA Laranjeira, MG Hollingshead, D Nguyen… - Scientific Reports, 2023 - nature.com
Role of DNA damage and demethylation on anticancer activity of DNA methyltransferase
inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene …
inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene …
[HTML][HTML] Inhibition of neddylation modification sensitizes pancreatic cancer cells to gemcitabine
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
USA with a 5-year survival rate less than 3% to 5%. Gemcitabine remains as a standard care …
USA with a 5-year survival rate less than 3% to 5%. Gemcitabine remains as a standard care …